Japan’s health ministry panel on Thursday approved the commercialisation of two regenerative medicine products prepared from iPS cells, the first of their kind in the world.
The two drugs, ReHeart developed by Cuorips, a start-up originating from the University of Osaka, and Amchepry by Sumitomo Pharma and Racthera, will be used for patients with severe heart failure stemming from ischemic cardiomyopathy and Parkinson’s disease, respectively.
“I am very happy to see the first big step towards…
Comments